To assess effectiveness of Macugen for treatment of neovascular age-related macular degeneration by measuring the evolution of visual acuity. Treatment duration, frequency of administration and combination with other treatments will also be evaluated.
Study Type
OBSERVATIONAL
Enrollment
38
Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)
Pfizer Investigational Site
Aarschot, Belgium
Pfizer Investigational Site
Deurne, Belgium
Pfizer Investigational Site
Leuven, Belgium
Pfizer Investigational Site
Liège, Belgium
Change From Baseline to Final Visit in Visual Acuity (VA) Score
Best corrected VA score, assessed on the scale over time (best corrected VA score at Final Visit minus best corrected VA score at Baseline). Lower scores represent poorer eyesight and higher scores represent better eyesight with a value of 1 representing normal eyesight. A positive change in score represents an improvement in sight.
Time frame: Baseline, Month 24 or Early Termination
Number of Participants With Change in VA: Improvement
Investigator's clinical judgement of Improvement in status of vision as compared to the previous Macugen injection, calculated from measurement of the difference between the VA scores at the 2 visits.
Time frame: Months 3, 6, 9 and 12
Number of Participants With Change in VA: Stabilization
Investigator's clinical judgement as Stabilization in status of visual acuity as compared to the previous Macugen injection, determined from measurement difference between the VA scores at the 2 visits.
Time frame: Months 3, 6, 9 and 12
Number of Participants With Change in VA: Worsening
Investigator's clinical judgement as Worsening in status of vision as compared to the previous Macugen injection, determined from measurement difference between the VA scores at the 2 visits.
Time frame: Months 3, 6, 9 and 12
Duration of Treatment
Duration of treatment per participant calculated as: date of injection (for the last injection of Macugen) minus date of injection (for the first injection of Macugen).
Time frame: Baseline up to 28.4 months
Frequency of Macugen Administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Average frequency of Macugen administration per participant calculated as: (number of Macugen injections administered per participant - 1)/ duration of treatment.
Time frame: Baseline up to 28.4 months
Number of Participants Who Received Other Concomitant Age Related Macular Degeneration (AMD) Treatments
Derived by whether a participant took any other AMD treatments at any time (at any Study Treatment Visit).
Time frame: Months 3, 6, 9 and 12